MX376500B - Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma. - Google Patents

Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma.

Info

Publication number
MX376500B
MX376500B MX2018008131A MX2018008131A MX376500B MX 376500 B MX376500 B MX 376500B MX 2018008131 A MX2018008131 A MX 2018008131A MX 2018008131 A MX2018008131 A MX 2018008131A MX 376500 B MX376500 B MX 376500B
Authority
MX
Mexico
Prior art keywords
preparation
crystal
crystalline form
kinase inhibitor
btk kinase
Prior art date
Application number
MX2018008131A
Other languages
English (en)
Other versions
MX2018008131A (es
Inventor
Guaili Wu
Xi Lu
Yun Lu
Zhenjun Qiu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2018008131A publication Critical patent/MX2018008131A/es
Publication of MX376500B publication Critical patent/MX376500B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una forma cristalina de un inhibidor de la BTK quinasa y al método de preparación de la misma. Específicamente, la presente invención se refiere a un cristal tipo I de la (R)-4-amino-1-(1-(but-2-inoil)pirrolidin-3-il)3-(4-(2,6-difluorofenoxi)fenil)-1H-pirrolo[2,3-d]piridazin-7(6H)-ona (el compuesto en la fórmula (I)) y al método de preparación del mismo. El cristal tipo I del compuesto de fórmula (I) obtenido mediante la presente invención tiene una buena estabilidad tanto una buena estabilidad del cristal como una buena estabilidad química, y el solvente del cristal utilizado tiene una baja toxicidad y es poco residual haciéndolo, de esta manera, más adecuado para su uso en el tratamiento clínico.
MX2018008131A 2016-01-05 2016-12-20 Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma. MX376500B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610006080 2016-01-05
PCT/CN2016/111051 WO2017118277A1 (zh) 2016-01-05 2016-12-20 一种btk激酶抑制剂的结晶形式及其制备方法

Publications (2)

Publication Number Publication Date
MX2018008131A MX2018008131A (es) 2018-09-03
MX376500B true MX376500B (es) 2025-03-07

Family

ID=59273271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008131A MX376500B (es) 2016-01-05 2016-12-20 Forma cristalina del inhibidor de la btk quinasa y método de preparación de la misma.

Country Status (15)

Country Link
US (1) US10626116B2 (es)
EP (1) EP3372607B1 (es)
JP (1) JP6913274B2 (es)
KR (1) KR102688907B1 (es)
CN (1) CN107406453B (es)
AU (1) AU2016384921C1 (es)
BR (1) BR112018012106B1 (es)
CA (1) CA3009256C (es)
ES (1) ES2875384T3 (es)
HK (1) HK1243419B (es)
MX (1) MX376500B (es)
PL (1) PL3372607T3 (es)
RU (1) RU2728827C2 (es)
TW (1) TWI726030B (es)
WO (1) WO2017118277A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602752B (zh) 2016-02-12 2021-07-02 阿克苏诺贝尔化学品国际有限公司 制备高级亚乙基胺和亚乙基胺衍生物的方法
KR20200144546A (ko) * 2018-04-13 2020-12-29 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤로아미노피리다지논 화합물 및 이의 중간체의 제조 방법
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
US20220362357A1 (en) 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
CN111499642A (zh) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202100527A (zh) * 2019-05-31 2021-01-01 大陸商江蘇恆瑞醫藥股份有限公司 一種固體分散體及其製備方法
CN110372562B (zh) 2019-07-09 2021-04-06 上海再启生物技术有限公司 一种btk激酶抑制剂关键中间体的晶型及其制备方法
CN112745255A (zh) * 2019-10-30 2021-05-04 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的制备方法
KR20230050363A (ko) * 2020-08-10 2023-04-14 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 질환의 치료에 있어서 btk 저해제의 용도
UY39377A (es) 2020-08-14 2022-03-31 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
WO2022104150A1 (en) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
WO2022261138A1 (en) 2021-06-08 2022-12-15 Tg Therapeutics, Inc. Disrupted ikaros signaling as biomarker for btk inhibition
CN114751850B (zh) * 2022-06-06 2023-08-25 上海再启生物技术有限公司 一种btk激酶抑制剂关键中间体的制备方法
CN114989062A (zh) * 2022-07-04 2022-09-02 上海再启生物技术有限公司 一种btk激酶抑制剂中间体的晶型及其制备方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2026133229A1 (en) 2024-12-20 2026-06-25 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5271897B2 (ja) * 2006-05-31 2013-08-21 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ ポリ(ADP−リボース)ポリメラーゼ(PARP)の阻害剤としての、ピロロ[1,2−a]ピラジン−1(2H)−オン及びピロロ[1,2−d][1,2,4]トリアジン−1(2H)−オン誘導体
EP2139487B1 (en) * 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CN102711765A (zh) * 2009-11-16 2012-10-03 加利福尼亚大学董事会 激酶抑制剂
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP2890691B1 (en) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
KR102073797B1 (ko) * 2014-07-07 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 단백질 키나제 저해제로서의 아미노피리다지논 화합물
EP3626239B1 (en) * 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor

Also Published As

Publication number Publication date
EP3372607A4 (en) 2018-10-03
RU2728827C2 (ru) 2020-07-31
BR112018012106A2 (pt) 2018-12-04
CN107406453A (zh) 2017-11-28
KR102688907B1 (ko) 2024-07-29
EP3372607B1 (en) 2021-04-28
RU2018125277A3 (es) 2020-02-28
CN107406453B (zh) 2018-12-28
CA3009256A1 (en) 2017-07-13
HK1243419B (zh) 2019-11-22
PL3372607T3 (pl) 2021-09-20
CA3009256C (en) 2023-08-22
TWI726030B (zh) 2021-05-01
JP6913274B2 (ja) 2021-08-04
AU2016384921C1 (en) 2021-05-20
US10626116B2 (en) 2020-04-21
BR112018012106B1 (pt) 2023-12-12
KR20180099787A (ko) 2018-09-05
MX2018008131A (es) 2018-09-03
JP2019500357A (ja) 2019-01-10
ES2875384T3 (es) 2021-11-10
US20190010161A1 (en) 2019-01-10
WO2017118277A1 (zh) 2017-07-13
TW201725207A (zh) 2017-07-16
RU2018125277A (ru) 2020-02-07
AU2016384921A1 (en) 2018-07-26
EP3372607A1 (en) 2018-09-12
AU2016384921B2 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
JOP20250289A1 (ar) صور بلورية جديدة
BR112018012106A2 (pt) forma cristalina de inibidor de btk quinase e método de preparação da mesma
CY1122468T1 (el) Κρυσταλλικη μορφη διθειικου αναστολεα κινασης jak και μια μεθοδος παρασκευης αυτου
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12020550575A1 (en) Salts of pi3k inhibitor and processes for their preparation
GEP201706735B (en) Kinase inhibitors
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EP4248988A3 (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
WO2015132799A3 (en) Heterocyclic compounds
TN2010000131A1 (en) Polo-like kinase inhibitors
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201491671A1 (ru) Гетероциклильные соединения
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
PH12016500885A1 (en) Novel heterocyclic compounds
PH12019500681A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
CY1121484T1 (el) Μορφες αλατος και κρυσταλλου ενος αναστολεα plk-4
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
TW200745066A (en) Novel PTP1B inhibitors

Legal Events

Date Code Title Description
FG Grant or registration